LT2922850T - Junginiai ir jų panaudojimo būdai - Google Patents

Junginiai ir jų panaudojimo būdai

Info

Publication number
LT2922850T
LT2922850T LTEP13857585.7T LT13857585T LT2922850T LT 2922850 T LT2922850 T LT 2922850T LT 13857585 T LT13857585 T LT 13857585T LT 2922850 T LT2922850 T LT 2922850T
Authority
LT
Lithuania
Prior art keywords
compounds
methods
Prior art date
Application number
LTEP13857585.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
Rene M. Lemieux
Janeta Popovici-Muller
Francesco G. Salituro
Jeffrey O. Saunders
Jeremy M. Travins
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Publication of LT2922850T publication Critical patent/LT2922850T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP13857585.7T 2012-11-22 2013-11-21 Junginiai ir jų panaudojimo būdai LT2922850T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (1)

Publication Number Publication Date
LT2922850T true LT2922850T (lt) 2018-09-10

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13857585.7T LT2922850T (lt) 2012-11-22 2013-11-21 Junginiai ir jų panaudojimo būdai

Country Status (36)

Country Link
US (2) US10087172B2 (OSRAM)
EP (2) EP3456719A1 (OSRAM)
JP (2) JP6333277B2 (OSRAM)
KR (1) KR20150085079A (OSRAM)
CN (2) CN108727307A (OSRAM)
AR (1) AR093598A1 (OSRAM)
AU (2) AU2013347771B2 (OSRAM)
BR (1) BR112015011830A2 (OSRAM)
CA (1) CA2893510C (OSRAM)
CL (1) CL2015001392A1 (OSRAM)
CR (1) CR20150316A (OSRAM)
CY (1) CY1120581T1 (OSRAM)
DK (1) DK2922850T3 (OSRAM)
EA (2) EA030646B1 (OSRAM)
EC (1) ECSP15026557A (OSRAM)
ES (1) ES2690390T3 (OSRAM)
HR (1) HRP20181628T1 (OSRAM)
HU (1) HUE040111T2 (OSRAM)
IL (1) IL238958B (OSRAM)
LT (1) LT2922850T (OSRAM)
MX (1) MX367389B (OSRAM)
MY (1) MY177344A (OSRAM)
NZ (1) NZ708382A (OSRAM)
PE (1) PE20151072A1 (OSRAM)
PH (2) PH12015501150B1 (OSRAM)
PL (1) PL2922850T3 (OSRAM)
PT (1) PT2922850T (OSRAM)
RS (1) RS57859B1 (OSRAM)
SA (1) SA515360469B1 (OSRAM)
SG (2) SG11201504049VA (OSRAM)
SI (1) SI2922850T1 (OSRAM)
SM (1) SMT201800504T1 (OSRAM)
TR (1) TR201812360T4 (OSRAM)
TW (2) TW201906825A (OSRAM)
UA (1) UA117360C2 (OSRAM)
WO (3) WO2014079011A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EP3954686A1 (en) 2012-11-16 2022-02-16 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
HK1213889A1 (zh) 2012-11-21 2016-07-15 安吉奥斯医药品有限公司 殼氨醯胺酶抑制劑及使用方法
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20150091389A (ko) * 2012-12-03 2015-08-10 칼리테라 바이오사이언시즈 인코포레이티드 글루타미나제의 헤테로사이클릭 억제제에 의한 암 치료
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
KR20160100407A (ko) * 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
BR112016021620A2 (pt) * 2014-03-21 2018-07-10 Agios Pharmaceuticals Inc compostos e seus métodos de uso
EA033919B1 (ru) 2014-04-30 2019-12-10 Пфайзер Инк. Соединённые циклоалкилом дигетероциклические производные
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
HUE049600T2 (hu) * 2014-07-03 2020-10-28 Univ Texas GLS1 inhibitorok betegségek kezelésére
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) * 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
CA2990457C (en) * 2015-06-30 2024-07-02 Board Of Regents, University Of Texas System PYRROLIDINYL AND PIPERIDINYL DERIVATIVES AND RELATED PHARMACEUTICAL COMPOSITIONS USEFUL AS GLS1 INHIBITORS
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
CN106890184B (zh) * 2015-12-18 2019-06-25 诺言医药科技(上海)有限公司 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用
KR102777513B1 (ko) 2015-12-22 2025-03-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 (r)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-n-메틸-1h-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
BR112019003533A2 (pt) * 2016-08-25 2019-05-21 Calithera Biosciences Inc. terapia de combinação com inibidores de glutaminase
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
WO2020096916A2 (en) 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
WO2020191356A1 (en) * 2019-03-21 2020-09-24 Goncalves Marcus Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
DE69425882T2 (de) 1993-03-29 2001-01-11 Basf Ag 1-amino-3-phenoxy-propan-derivate als modulatoren bei multi-drug resistenz
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
CA2332325A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
EP1388734B1 (en) 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
BRPI0817393A2 (pt) 2007-11-19 2015-03-31 Genentech Inc Anticorpo monoclonal, polipetídeo solúvel isolado, método de inibição do progresso de tumores, método de inibição de emt em células e método de determinação se um tumor reagirá a um antagonista de b2 ou um antagonista de notch
WO2009111067A2 (en) 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
JP2012524280A (ja) 2009-04-17 2012-10-11 オーエスアイ・ファーマシューティカルズ,エルエルシー 上皮成長因子受容体キナーゼ阻害剤に対する抗がん反応を予測するための生物学的マーカー
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
ES2812457T3 (es) 2010-06-23 2021-03-17 Univ Louisville Res Found Inc Uso de ácidos grasos en procedimientos para detectar cáncer
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EA026656B1 (ru) * 2011-11-21 2017-05-31 Калитера Байосайенсиз Инк. Гетероциклические ингибиторы глютаминазы
RU2014141114A (ru) 2012-03-15 2016-05-10 Дзе Рисерч Фаундейшн Фор Дзе Стейт Юниверсити Оф Нью Йорк Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина
HK1213889A1 (zh) 2012-11-21 2016-07-15 安吉奥斯医药品有限公司 殼氨醯胺酶抑制劑及使用方法
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
BR112016021620A2 (pt) 2014-03-21 2018-07-10 Agios Pharmaceuticals Inc compostos e seus métodos de uso

Also Published As

Publication number Publication date
AU2018202954A1 (en) 2018-05-17
CA2893510A1 (en) 2014-05-30
EA201590987A1 (ru) 2015-12-30
ECSP15026557A (es) 2016-01-29
US10087172B2 (en) 2018-10-02
HUE040111T2 (hu) 2019-02-28
MY177344A (en) 2020-09-13
US20190084976A1 (en) 2019-03-21
EA201890754A1 (ru) 2018-08-31
WO2014079150A1 (en) 2014-05-30
RS57859B1 (sr) 2018-12-31
SMT201800504T1 (it) 2018-11-09
TWI629268B (zh) 2018-07-11
AU2013347771B2 (en) 2018-02-01
PH12015501150A1 (en) 2015-08-17
ES2690390T3 (es) 2018-11-20
PT2922850T (pt) 2018-10-15
MX367389B (es) 2019-08-19
JP2018150316A (ja) 2018-09-27
CL2015001392A1 (es) 2016-04-22
EP2922850A4 (en) 2016-05-18
CN104936954A (zh) 2015-09-23
JP2016500082A (ja) 2016-01-07
HK1214593A1 (en) 2016-07-29
PE20151072A1 (es) 2015-08-26
WO2014079136A1 (en) 2014-05-30
US10689375B2 (en) 2020-06-23
CN104936954B (zh) 2018-08-14
PL2922850T3 (pl) 2018-12-31
TW201427963A (zh) 2014-07-16
AU2013347771A1 (en) 2015-06-11
TW201906825A (zh) 2019-02-16
SG11201504049VA (en) 2015-07-30
NZ708382A (en) 2020-04-24
EA030646B1 (ru) 2018-09-28
TR201812360T4 (tr) 2018-09-21
IL238958A0 (en) 2015-07-30
CY1120581T1 (el) 2019-07-10
DK2922850T3 (en) 2018-10-08
SA515360469B1 (ar) 2017-07-11
BR112015011830A2 (pt) 2017-07-11
PH12017502141A1 (en) 2019-02-27
EP2922850A1 (en) 2015-09-30
CA2893510C (en) 2021-01-19
UA117360C2 (uk) 2018-07-25
EP2922850B1 (en) 2018-07-18
PH12015501150B1 (en) 2018-05-04
AR093598A1 (es) 2015-06-10
CR20150316A (es) 2015-08-28
JP6333277B2 (ja) 2018-05-30
SG10201609940RA (en) 2016-12-29
SI2922850T1 (sl) 2018-10-30
WO2014079011A1 (en) 2014-05-30
IL238958B (en) 2019-09-26
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
HRP20181628T1 (hr) 2018-12-14
EP3456719A1 (en) 2019-03-20
US20150291576A1 (en) 2015-10-15
CN108727307A (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
SG10201609940RA (en) Compounds and their methods of use
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
ZA201502503B (en) Hppd variants and methods of use
ZA201405248B (en) Anesthetic compounds and related methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2879676A4 (en) SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
ZA201406082B (en) Use of ccr3-inhibitors
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201408856B (en) Heteroaryl compounds and methods of use thereof
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
AU2012900650A0 (en) Compounds and methods of their use
AU2012900651A0 (en) Compounds and methods of their use
GB201213726D0 (en) Novel compounds and their use
AU2012903090A0 (en) Compounds and methods of their use - IV
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment